ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

PFS increase but no OS increase for niraparib in advanced ovarian cancer

ESMO 2024: Highlights and analysis

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy

ESMO 2024: Latest in bladder cancer - expert review